UBX vs. ATOS, ANRO, IVA, NVCT, MGX, DBVT, TARA, ELUT, IGMS, and MIST
Should you be buying Unity Biotechnology stock or one of its competitors? The main competitors of Unity Biotechnology include Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), Metagenomi (MGX), DBV Technologies (DBVT), Protara Therapeutics (TARA), Elutia (ELUT), IGM Biosciences (IGMS), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry.
Unity Biotechnology vs.
Atossa Therapeutics (NASDAQ:ATOS) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.
Atossa Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 723.53%. Unity Biotechnology has a consensus target price of $7.33, indicating a potential upside of 323.89%. Given Atossa Therapeutics' higher probable upside, analysts clearly believe Atossa Therapeutics is more favorable than Unity Biotechnology.
Atossa Therapeutics received 63 more outperform votes than Unity Biotechnology when rated by MarketBeat users. However, 66.67% of users gave Unity Biotechnology an outperform vote while only 65.12% of users gave Atossa Therapeutics an outperform vote.
Atossa Therapeutics has higher earnings, but lower revenue than Unity Biotechnology. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 29.5% of Unity Biotechnology shares are owned by institutional investors. 7.6% of Atossa Therapeutics shares are owned by insiders. Comparatively, 5.8% of Unity Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Unity Biotechnology had 4 more articles in the media than Atossa Therapeutics. MarketBeat recorded 4 mentions for Unity Biotechnology and 0 mentions for Atossa Therapeutics. Atossa Therapeutics' average media sentiment score of 0.84 beat Unity Biotechnology's score of 0.82 indicating that Atossa Therapeutics is being referred to more favorably in the media.
Atossa Therapeutics' return on equity of -35.74% beat Unity Biotechnology's return on equity.
Atossa Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Unity Biotechnology has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
Summary
Atossa Therapeutics beats Unity Biotechnology on 9 of the 14 factors compared between the two stocks.
Get Unity Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unity Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:UBX) was last updated on 1/21/2025 by MarketBeat.com Staff
